Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
Type:
Grant
Filed:
October 5, 2020
Date of Patent:
May 7, 2024
Assignee:
Amgen Inc.
Inventors:
Marc Alain Gavin, Gunasekaran Kannan, Li Li, Joshua Thomas Pearson, Margaret Karow
Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13R?2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.
Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
Type:
Grant
Filed:
October 7, 2020
Date of Patent:
May 7, 2024
Assignee:
Amgen Inc.
Inventors:
Eric Alan Butz, Christy Ann Thomson, Marc Alain Gavin, Ian Nevin Foltz, Dong Xia, Dina N. Alcorn, Randal Robert Ketchem, Ai Ching Lim, Kathy Manchulenko, Laura Sekirov, Kelly Ann Berry, Cyr Clovis Chua De Imus, Neeraj Jagdish Agrawal, Gunasekaran Kannan, Li Li
Abstract: The invention features multi-specific fusion protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to IL-12 or IL-18.
Type:
Grant
Filed:
December 1, 2023
Date of Patent:
May 7, 2024
Assignee:
Altor Bioscience, LLC.
Inventors:
Warren D. Marcus, Robert Newman, Bai Liu, Lijing You, Lin Kong, Peter Rhode, Hing C. Wong
Abstract: One aspect of the invention provides a method of treating a chronic wound including administering to the wound at least one agent from a delivery system wherein the agent induces sequential conversion of a first population of wound macrophages in the wound to M2A macrophages and a second population of wound macrophages to M2C macrophages. The sequential conversion of the wound macrophages promotes tissue remodeling.
Abstract: The present disclosure is directed to methods of treating atopic dermatitis comprising administering to a subject in need thereof a therapeutically effective amount of an anti-IL-13 antibody, or antigen binding fragment thereof, thereby treating atopic dermatitis in the subject.
Type:
Grant
Filed:
March 16, 2022
Date of Patent:
April 23, 2024
Assignee:
Receptos, LLC
Inventors:
Sarah Harris, Erin Babcock, Cristian Rodriguez
Abstract: The invention features multi-specific fusion protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to IL-7 or IL-21.
Abstract: Provided are blocking agents to IL-1?, IL-1?, or IL-1R activity for use in combination with radiotherapy for treating cancer patients in which radiotherapy treatment induces IL-1?, IL-1? or both in their circulation.
Abstract: The present invention is directed to QTY CCR9 and CXCR2 variant Fc receptor fusion proteins, methods for the preparation thereof and methods of use thereof.
Type:
Grant
Filed:
July 29, 2022
Date of Patent:
March 26, 2024
Assignees:
Massachusetts Institute of Technology, Avalon GloboCare Corp.
Inventors:
Shuguang Zhang, David Jin, Rui Qing, Uwe Sleytr
Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.
Type:
Grant
Filed:
December 2, 2020
Date of Patent:
March 26, 2024
Assignees:
Singapore Health Services PTE LTD., National University of Singapore
Inventors:
Stuart Alexander Cook, Sebastian Schaefer
Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through a high affinity interleukin receptor. The antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prevention of immune related disorders such as Type 1 Diabetes.
Abstract: Provided are anti-GM-CSF antibodies or fragments thereof including humanized antibodies and fragments. Also provided are uses of the antibodies and fragments for therapeutic, diagnostic and prognostic purposes. Therapeutic uses of the antibodies and fragments, for example include the treatment of inflammatory and autoimmune diseases and disorders.
Type:
Grant
Filed:
December 2, 2020
Date of Patent:
March 12, 2024
Assignee:
I-Mab Biopharma (Hangzhou) Co., Ltd.
Inventors:
Zhengyi Wang, Lei Fang, Bingshi Guo, Jingwu Zang
Abstract: The invention is in the field of antibodies useful in therapeutic and diagnostics applications targeting CD127, the alpha chain of the IL7 receptor, and provides in particular humanized monoclonal antibodies against CD127, particularly human CD127, therapeutic uses thereof, and diagnostics applications.
Type:
Grant
Filed:
June 30, 2021
Date of Patent:
March 12, 2024
Assignee:
OSE IMMUNOTHERAPEUTICS
Inventors:
Nicolas Poirier, Caroline Mary, Bernard Vanhove, Virginie Thepenier
Abstract: Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7R?). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.
Type:
Grant
Filed:
April 16, 2021
Date of Patent:
March 5, 2024
Assignee:
Bristol Myers-Squibb Company
Inventors:
Aaron Paul Yamniuk, Scott Ronald Brodeur, Ekaterina Deyanova, Richard Yu-Cheng Huang, Yun Wang, Alfred Robert Langish, Guodong Chen, Stephen Michael Carl, Hong Shen, Achal Mukundrao Pashine, Lin Hui Su
Abstract: Disclosed herein are interleukin (IL) 15 conjugates and use in the treatment of one or more indications. Also described herein include pharmaceutical compositions and kits comprising one or more of IL-15 conjugates.
Type:
Grant
Filed:
August 25, 2020
Date of Patent:
March 5, 2024
Assignee:
SYNTHORX, INC.
Inventors:
Carolina E. Caffaro, Jerod Ptacin, Marcos Milla
Abstract: The present invention is directed to antigen binding proteins and in particular to IL-1? antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.
Type:
Grant
Filed:
January 15, 2021
Date of Patent:
February 27, 2024
Assignee:
Agency for Science, Technology and Research
Abstract: Described herein are materials and methods for stratifying risk for reactivation of a latent viral infection, such as CMV infection. The methods are particularly useful for immune compromised subjects. Also described herein are interventions, including therapeutic, prophylactic, and monitoring interventions, for subjects determined to be at elevated risk.
Type:
Grant
Filed:
May 14, 2018
Date of Patent:
February 27, 2024
Assignee:
UNIVERSITY OF MIAMI
Inventors:
Krishna Komanduri, Eric Wieder, Jose Camargo, Erik Kimble
Abstract: The disclosure relates to compounds specific for IL23A and BAFF, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
Type:
Grant
Filed:
October 22, 2020
Date of Patent:
January 30, 2024
Assignees:
Boehringer Ingelheim International GmbH, MacroGenics, Inc.
Inventors:
Sanjaya Singh, Qi Pan, Rachel Rebecca Barrett, Leslie S. Johnson, Pankaj Gupta, Sarah Low, Haixia Wu